Document is current
Any future updates will be listed below
-
Authors
Bouchi, Ryotaro
Kondo, Tatsuya
Ohta, Yasuharu
Goto, Atsushi
Tanaka, Daisuke
Satoh, Hiroaki
Yabe, Daisuke
Nishimura, Rimei
Harada, Norio
Kamiya, Hideki
Suzuki, Ryo
Yamauchi, Toshimasa
,
Yamauchi, Toshimasa
Bouchi, Ryotaro
Kondo, Tatsuya
Ohta, Yasuharu
Harada, Norio
Kamiy, Hideki
Yamauchi, Toshimasa
- License Information
-
More Information
Article History
Received: 25 January 2024
Accepted: 8 February 2024
First Online: 11 July 2024
Declarations
:
: Ryotaro Bouchi: Honoraria (Sumitomo Pharma; AstraZeneca; Novo Nordisk Pharma), and Research funding (Sumitomo Pharma) Yasuharu Ohta: Research funding (Manpei Suzuki Diabetes Foundation), and Subsidies or Donations (Sumitomo Pharma; Nippon Boehringer Ingelheim; Novo Nordisk Pharma). Daisuke Yabe: Honoraria (Novo Nordisk Pharma; Nippon Boehringer Ingelheim; Eli Lilly Japan; Sanofi; Kyowa Kirin; Sumitomo Pharma), and Research funding (Terumo Corporation; Nippon Boehringer Ingelheim), and Endowed departments by commercial entities (Novo Nordisk Pharma; Taisho Pharmaceutical; ARKRAY). Rimei Nishimura: Honoraria (Sanofi; Medtronic; Nippon Boehringer Ingelheim; KISSEI PHARMACEUTICAL; Eli Lilly Japan; Novo Nordisk Pharma; Astellas Pharma; Abbott Japan; Sumitomo Pharma; AstraZeneca; KOWA; ONO PHARMACEUTICAL; Taisho Pharmaceutical), and Research funding (Mitsubishi Electric), and Subsidies or Donations (Taisho Pharmaceutical; Nippon Boehringer Ingelheim; Abbott Japan; Sumitomo Pharma; Eli Lilly Japan; Arkley). Norio Harada: Research funding (Mitsubishi Tanabe Pharma; Eli Lilly Japan; Nippon Boehringer Ingelheim; ONO PHARMACEUTICAL). Hideki Kamiya: Honoraria (Novo Nordisk Pharma; Sanofi; Sumitomo Pharma; Eli Lilly Japan; Nippon Boehringer Ingelheim; DAIICHI SANKYO; AstraZeneca; ONO PHARMACEUTICAL; KISSEI PHARMACEUTICAL; Mitsubishi Tanabe Pharma; KOWA; Novartis Pharma; MSD; SANWA KAGAKU KENKYUSHO; Otsuka Pharmaceutical), and Research funding (ONO PHARMACEUTICAL; Eli Lilly Japan; KISSEI PHARMACEUTICAL), and Subsidies or Donations (ONO PHARMACEUTICAL; Taisho Pharmaceutical; Sumitomo Pharma; Takeda Pharmaceutical; Mitsubishi Tanabe Pharma; JAPAN TOBACCO; Novo Nordisk Pharma). Ryo Suzuki: Honoraria (Novo Nordisk Pharma; Sanofi; Sumitomo Pharma; Astellas Pharma; KOWA; MSD; Eli Lilly Japan; Mitsubishi Tanabe Pharma; TEIJIN PHARMA), and Research funding (Sumitomo Pharma), and Subsidies or Donations (Nippon Boehringer Ingelheim). Toshimasa Yamauchi: Honoraria (ONO PHARMACEUTICAL; Takeda Pharmaceutical; Sumitomo Pharma; TEIJIN PHARMA; Nippon Boehringer Ingelheim; Novo Nordisk Pharma), and Research funding (KOWA; Minophagen Pharmaceutical; NIPRO CORPORATION; Kyowa Kirin), and Subsidies or Donations (Novo Nordisk Pharma; Mitsubishi Tanabe Pharma; Kyowa Kirin; Takeda Pharmaceutical; ONO PHARMACEUTICAL; Sumitomo Pharma), and Endowed departments by commercial entities (ONO PHARMACEUTICAL; Mitsubishi Tanabe Pharma; Novo Nordisk Pharma; Nippon Boehringer Ingelheim; KOWA; NITTO BOSEKI; Asahi Mutual Life Insurance Company). Dr Daisuke Yabe, Dr Norio Harada, Dr Hideki Kamiya, Dr Toshimasa Yamauchi are Editorial Board members of Journal of Diabetes Investigation and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication.
